Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Inclusion Criteria

• •Celecoxib Treated Patients:
• •Diagnosis of FAP based on the expression of the FAP phenotype.
• •Celecoxib treatment prescribed outside of a clinical trial setting with expected duration of celecoxib treatment of at least six months.
• •Historical/Concurrent Control Patients:
• •Diagnosis of FAP based on the expression of the FAP phenotype.
• •Be greater than or equal to 12 years old at the time of study enrollment.
• •Have an endoscopically assessable colonic, rectal, ileal pouch and/or gastroduodenal segment.
• •For the group of post-surgical patients, IRA or IPAA performed from 1985 onward (in order to assure standardized surgical techniques and post-surgical management). Patients whose primary colorectal surgery was performed prior to 1985 will not be eligible to serve as historical controls.